Eurofins Genomics and Hurdle to Increase Access and Innovation in testing Globally

Eurofins Genomics and Hurdle have announced a transformative collaboration aimed at revolutionizing the application of omics technologies across multiple sectors globally.

This partnership will enhance the development, accessibility, and implementation of complex biomarker technologies, advancing fields from drug discovery, to healthcare and agriculture.

By combining Hurdle’s advanced technology platform with Eurofins Genomics’ extensive global laboratory network, this collaboration is poised to set new standards in the speed and efficiency with which omics tests are used in various industries. The partnership will not only improve upon current systems and applications but also accelerate future innovation in complex biomarker technologies.

The collaboration transcends traditional boundaries, offering significant advancements from basic research, to consumer health, food security and pharma. This strategic partnership is among the first of its kind and both teams are proud to be advancing science together and implementing complex biomarkers for the benefit of all.

Dr. Tom Stubbs, Co-founder of Hurdle, emphasized the innovative potential of the partnership: “This partnership marks a watershed moment in the field of omics technologies. It accelerates innovation, drastically improves global accessibility, and expands the applications of these technologies. This partnership will greatly reduce the time society needs to wait for breakthrough advances to become ubiquitous. From precision medicine to food security, we will be supporting the best researchers in the world to deliver on a brighter future for all.”

About Hurdle

Hurdle, a brand of Chronomics Inc., is a leader in biomarker infrastructure solutions. The platform manages end-to-end biomarker events in research and in-market settings. The platform fundamentally handles the technology, operational, informatics and AI layers needed to deliver biomarker events. Increasing access to and actionability of biomarkers for customers across sectors including healthcare, pharmaceuticals, and agriculture. Hurdle’s technology simplifies this complexity globally, making it an indispensable tool for organizations aiming to improve health outcomes and accelerate research and development. The platform supports the full lifecycle of biomarker diagnostics, from development to implementation, streamlining processes for organizations in pharma, R&D, healthcare, virtual care and more. For more information or to discuss potential collaborations, contact [email protected].

About Eurofins Genomics

Eurofins Genomics represents the genomic division within the Eurofins Scientific Group. With facilities in Europe, the United States and Asia, Eurofins Genomics is an internationally leading provider of DNA sequencing and genotyping services, DNA synthesis products and bioinformatics services for pharma, diagnostics, population genomics, consumer genomics, food, agriculture, biotechnological and research markets. The European branch is headquartered in Ebersberg, Germany. For further information, please visit